Cubist
Pharmaceuticals CBST today announced that it
submitted a Clinical Trial Application (CTA) to the Dutch Competent
Authority and Ethics Committee to initiate a first-in-human study of
CB-618 in the Netherlands. Discovered by Cubist, CB-618 is a novel,
broad-spectrum beta-lactamase inhibitor (BLI) investigational compound.
Based on in vitro studies, CB-618 has been shown to increase the
spectrum of activity of certain beta-lactam antibiotics.
(Beta-lactamases are enzymes produced by some bacteria that provide
resistance to certain beta-lactam antibiotics.)
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in